MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-10-2022
PLx Pharma Shares 2011-2026 | PLXP
Annual Shares PLx Pharma
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 23.7 M | 9.16 M | 8.92 M | 8.73 M | 7.02 M | 1.3 M | 1.18 M | 981 K | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 23.7 M | 981 K | 7.62 M |
Quarterly Shares PLx Pharma
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 28.6 M | 27.7 M | 27.5 M | 27.5 M | 26.9 M | 23.6 M | 16.4 M | 13.9 M | 9.16 M | 9.16 M | 9.16 M | 9.16 M | 8.92 M | 8.78 M | 8.75 M | 8.74 M | 8.74 M | 8.73 M | 8.73 M | 8.72 M | 8.7 M | 6.16 M | 4.38 M | 4.38 M | 4.38 M | 4.38 M | 10.3 M | 10.3 M | 10.3 M | 8.58 M | 8.55 M | 8.54 M | 8.54 M | 8.54 M | 5.75 M | - | 4.77 M | 4.43 M | 4.37 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 28.6 M | 4.37 M | 11.2 M |
Shares of other stocks in the Drug manufacturers industry
| Issuer | Shares | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
25.8 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Aerie Pharmaceuticals
AERI
|
46.3 M | - | - | $ 754 M | USA |
 |
Alimera Sciences
ALIM
|
25.6 M | - | - | $ 142 M | USA |
 |
Agile Therapeutics
AGRX
|
2.16 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
150 M | - | 0.86 % | $ 117 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
95.1 M | $ 21.64 | - | $ 2.06 B |  France |
 |
Canopy Growth Corporation
CGC
|
108 M | $ 1.03 | -3.27 % | $ 111 M |  Canada |
 |
Cronos Group
CRON
|
350 M | $ 2.59 | -0.77 % | $ 1.34 B | Canada |
 |
Catalent
CTLT
|
181 M | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
26.3 M | - | - | $ 50.1 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
14.1 M | $ 3.85 | -0.52 % | $ 54.1 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
50.8 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
Eagle Pharmaceuticals
EGRX
|
12.9 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
235 M | - | - | $ 28.9 M |  Irlanda |
 |
HEXO Corp.
HEXO
|
127 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Evoke Pharma
EVOK
|
3.34 M | - | - | $ 36.6 M | USA |
 |
Emergent BioSolutions
EBS
|
51.2 M | $ 10.78 | -2.27 % | $ 552 M | USA |
 |
Athenex
ATNX
|
6.54 M | - | -23.39 % | $ 1.76 M | USA |
 |
Jupiter Wellness
JUPW
|
54.4 M | - | - | $ 33.6 M | USA |
 |
Evolus
EOLS
|
62 M | $ 4.28 | -0.58 % | $ 265 M | USA |
 |
China Pharma Holdings
CPHI
|
17.5 M | $ 0.66 | 4.31 % | $ 11.5 M |  China |
 |
Harrow Health
HROW
|
32.6 M | $ 48.5 | -0.33 % | $ 1.58 B | USA |
 |
OrganiGram Holdings
OGI
|
256 M | $ 1.3 | -1.02 % | $ 402 M | Canada |
 |
Pacira BioSciences
PCRX
|
46.2 M | $ 21.69 | -0.18 % | $ 1 B | USA |
 |
Lannett Company
LCI
|
40.4 M | - | 1.15 % | $ 7.11 M | USA |
 |
Bausch Health Companies
BHC
|
365 M | $ 5.88 | -3.37 % | $ 2.15 B | Canada |
 |
Tilray
TLRY
|
618 M | $ 7.48 | -1.84 % | $ 4.62 B | Canada |
 |
Sundial Growers
SNDL
|
1.86 M | $ 1.49 | -0.67 % | $ 3.37 M | Canada |
 |
Neoleukin Therapeutics
NLTX
|
492 K | - | - | $ 193 M | Canada |
 |
Perrigo Company plc
PRGO
|
137 M | $ 14.38 | -1.51 % | $ 1.98 B | USA |
 |
cbdMD
YCBD
|
4.31 M | $ 0.72 | -3.59 % | $ 3.11 M | USA |
 |
Organogenesis Holdings
ORGO
|
132 M | $ 3.72 | -1.2 % | $ 490 M | USA |
 |
PetIQ
PETQ
|
29.1 M | - | 1.64 % | $ 400 M | USA |
 |
Aurora Cannabis
ACB
|
169 M | $ 3.37 | -2.06 % | $ 86.3 M | Canada |
 |
ProPhase Labs
PRPH
|
15.8 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
47.2 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
95.2 M | - | -4.76 % | $ 65.3 M | USA |
 |
Rockwell Medical
RMTI
|
23.3 M | $ 1.01 | -7.28 % | $ 23.6 M | USA |
 |
Relmada Therapeutics
RLMD
|
30.1 M | $ 3.75 | -6.38 % | $ 113 M | USA |
 |
OptiNose
OPTN
|
112 M | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
71 M | $ 11.78 | -1.42 % | $ 837 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
1.24 M | $ 2.77 | -2.69 % | $ 3.44 M | USA |
 |
Solid Biosciences
SLDB
|
40.8 M | $ 6.1 | -4.69 % | $ 249 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
42.7 M | - | - | $ 55.5 M | USA |
 |
SCYNEXIS
SCYX
|
47.9 M | $ 0.78 | -1.93 % | $ 37.3 M | USA |
 |
Veru
VERU
|
135 M | $ 2.25 | -2.17 % | $ 303 M | USA |
 |
Tricida
TCDA
|
51.3 M | - | - | $ 3.25 M | USA |
 |
TherapeuticsMD
TXMD
|
10.4 M | $ 2.4 | -1.23 % | $ 25.1 M | USA |
 |
Viatris
VTRS
|
1.21 B | $ 15.94 | -1.19 % | $ 19.3 B | USA |